This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Inflammation and Acute Coronary Syndromes (SPUM-ACS)

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by University of Zurich
University of Bern
University Hospital, Geneva
University of Lausanne Hospitals
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: October 22, 2009
Last updated: September 8, 2016
Last verified: September 2016

Subproject 1: Optimize prevention after acute coronary syndromes (ACS) by improving caregiver and patient education (

Subproject 2: Discover novel genomic biomarkers of ACS in leukocyte subsets by means of analyzing gene expression profiles and function

Subproject 3: Evaluate novel diagnostic and prognostic biomarkers in soluble form in blood/plasma and urine

Subproject 5: Visualize the vulnerable plaque using intravascular ultrasound/optical coherence tomography (IVUS/OCT) and correlate with outcome and biomarkers

Subproject 7: Characterize the effects of inflammation on progenitor/stem cell-mediated repair after ACS by means of analyzing gene expression profiles and function

Acute Coronary Syndromes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Major adverse cardiovascular events (MACE) in overall population, defined as composite of cardiac death, myocardial infarction or ischemia-driven revascularization [ Time Frame: 30 days and 12 months follow-up ]

Secondary Outcome Measures:
  • SP2/SP3/SP5: temporal change in biomarkers (12 months). [ Time Frame: SP2/SP3/SP5: 13 months ]
  • Correlation with plaque burden and neointimal thickness assessed by IVUS/OCT imaging in ST segment elevation myocardial infarction (STEMI) subgroup (13 months) [ Time Frame: 13 months ]

Biospecimen Retention:   Samples With DNA
Blood, Thrombus, blood cells, urine

Estimated Enrollment: 4000
Study Start Date: October 2009
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients presenting with Acute Coronary Syndromes

3 control groups:

  • patients with stable coronary artery disease
  • healthy controls (blood bank)
  • peripheral artery occlusive disease (CLI/ALI)

Inclusion Criteria:

  • All patients with age ≥ 18 years presenting within 5 days (preferably within 72 hours) after pain onset with the main diagnosis of ACS (acute myocardial infarction: STEMI /NSTEMI and threatened infarction: unstable angina pectoris), who enter the hospital: The patients show symptoms, which are compatible with angina pectoris (chest pain, dyspnoea) and at least one of the following characteristics:

    • persistent ST-segment elevation or depression, T inversion or dynamic ECG changes, new left bundle branch block (LBBB)
    • Evidence of positive troponin by local laboratory reference values with a rise and/or fall in serial troponin levels
    • known coronary artery disease, specified as status after myocardial infarction, CABG, or PCI or newly documented ≥50% stenosis of an epicardial coronary artery during the initial catheterization

Exclusion Criteria:

  • Severe physical disability,
  • Dementia (inability to comprehend study), OR
  • Less than 1 year of life expectancy (for non-cardiac reasons).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01000701

Contact: Thomas F Luscher, MD 0041 44 255 ext 2121
Contact: Christian M Matter, MD 0041 44 635 ext 6467

University Hospital, Bern Recruiting
Bern, Switzerland
Contact: Stephan Windecker, MD   
Principal Investigator: Stephan Windecker, MD         
Sub-Investigator: Lorenz Raeber, MD         
Sub-Investigator: Peter Jueni, MD         
Sub-Investigator: Giulio G Stefanini         
University Hospital, Geneva Recruiting
Geneva, Switzerland, 1211
Contact: François Mach, MD   
Contact: Pierre-Frederic Keller, MD         
Principal Investigator: Francois Mach, MD         
Sub-Investigator: Pierre-Frederic Keller, MD         
Sub-Investigator: Sebastian Carballo, MD         
Sub-Investigator: David Carballo, MD         
Sub-Investigator: Thomas Perneger, MD, PhD         
Sub-Investigator: Marco Roffi, MD         
Sub-Investigator: Baris Gencer, MD         
University Hospital, Lausanne Recruiting
Lausanne, Switzerland
Contact: Nicolas Rodondi, MD   
Principal Investigator: Nicolas Rodondi, MD         
Sub-Investigator: Reto Auer, MD         
Sub-Investigator: David Nanchen, MD         
University Hospital, Zurich Recruiting
Zurich, Switzerland
Contact: Thomas F Luscher, MD   
Sub-Investigator: Christian M Matter, MD         
Sub-Investigator: Roland Klingenberg, MD         
Sub-Investigator: Ulf Landmesser, MD         
Sub-Investigator: Christian Templin, MD         
Sub-Investigator: Willibald Maier, MD         
Sub-Investigator: Lukas Altwegg, MD         
Principal Investigator: Thomas F Luscher, MD         
Sponsors and Collaborators
University of Zurich
University of Bern
University Hospital, Geneva
University of Lausanne Hospitals
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: University of Zurich Identifier: NCT01000701     History of Changes
Other Study ID Numbers: SPUM-ACS
Study First Received: October 22, 2009
Last Updated: September 8, 2016

Keywords provided by University of Zurich:
Clinical management

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on June 23, 2017